Subscribe to NRx Newsletter

Hope • Science • Life

We bring
hope to life

People facing life-threatening diseases need the possibility of tomorrow. We bring them hope through life-saving medicines, today.

We bring
hope to life

People facing life-threatening diseases need the possibility of tomorrow. We bring them hope through life-saving medicines, today.

Right to Try

Aviptadil Right to Try - for US-licensed physicians who wish to obtain Aviptadil under Right to Try law for Critical COVID-19 patients with no therapeutic alternative.

Right to Try

Aviptadil Right to Try - for US-licensed physicians who wish to obtain Aviptadil under Right to Try law for Critical COVID-19 patients with no therapeutic alternative.

Discover Our Pipeline

We go after the most critical medical conditions and unmet needs.

Discover Our Pipeline

We go after the most critical medical conditions and unmet needs.

We go after the most critical medical conditions and unmet needs.

We audaciously work to research, develop, and scale solutions to help people that desperately need them.

We accomplish our mission by directing deep scientific and clinical expertise towards innovative clinical development protocol, while simultaneously investing in scalability and stability to ensure our medicines are easily accessible to people around the world.

“We leverage proven science and clinical expertise to identify and apply medical solutions as immediately as possible.”

Jonathan C. Javitt, M.D., M.P.H.,
Chairman and Chief Executive Officer

Discovery Pipeline

We are advancing the development of multiple new therapeutic candidates in Phase 2, and Phase 3 trials.

Each product in our pipeline has expansive potential beyond their initial indicated targets, and with this, we can save more lives and hope becomes reality for even more people.

Highlights

Today, no medicine is approved to treat patients with bipolar depression suffering suicidal ideation.

NRX-101 is a patented, oral fixed-dose combination of two FDA-approved drugs: D-cycloserine, an NMDA receptor modulator; and Lurasidone, a 5-HT2a receptor antagonist.

NRX-101 An investigational, rapid-onset and sustained treatment for Bipolar Depression in patients with Acute Suicidal Ideation and Behavior.

ZYESAMI® has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA)for the treatment of Critical COVID-19 with respiratory failure, and is now in clinical trials.

ZYESAMI® (Aviptadil) is an investigational medicine for the treatment of Acute Respiratory Failure in patients with Critical COVID-19, and for the prevention of respiratory failure in patients with Severe COVID-19.

ZYESAMI® is a proprietary, shelf-stable formulation of Aviptadil, a synthetic form of human Vasoactive Intestinal Peptide (VIP). VIP is an endogenous substance produced by the body that, among other functions, helps protect cells against inflammatory conditions.

The BriLife™ vaccine is based on a previous, FDA-approved vaccine platform that was further optimized by IIBR and targeted towards COVID-19. Because BriLife™ is a self-propagating, live-virus vaccine, NRx anticipates rapid industrial scaleup and manufacturing. The vaccine will initially be delivered by traditional injection.

As the first generation COVID vaccines are increasingly challenged by rapid mutation of the Coronavirus, BriLife will be developed to rapidly scale at low cost and serve the needs of both the developed and the developing world.

Stories

A COVID-19 Story: Appreciating the value of a breath

We create innovative, life-saving treatments and bring hope to those facing life-altering conditions with no approved disease-modifying therapies or cures.